'Red Wine' Phase II Trial Including Takeda's Velcade Halted Early By GSK
This article was originally published in PharmAsia News
Executive Summary
A vaunted Phase II clinical trial based in part on a Takeda Pharmaceutical unit's Velcade (bortezomib) cancer drughas been halted for safety reasons